We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




License To Market Leukemia Service in Canada

By HospiMedica staff writers
Posted on 21 Aug 2007
Warnex (Laval, Canada) announced an exclusive license with Ipsogen SAS (Marseille, France) to market a service in Canada for the molecular diagnosis and classification of a group of leukemias.

The service is based on the analysis of variations in the JAK2 gene, to which Ipsogen has exclusive worldwide intellectual property rights. More...
A dominant gain-of-function V617F mutation in the JH2 kinase-like domain of JAK2A is present in a high proportion of patients with myeloproliferative disorders (MPD) such as polycythemia vera, essential thrombocythemia, and idiopathic myelofibrosis.

The president and CEO of Ipsogen, Vincent Fert, said, The medical community is now eager to integrate the JAK2 test into clinical practice. Ipsogen has recently launched the test both in the form of a product and a licensing program to react rapidly to these urgent medical needs.

Mark Busgang, president and CEO of Warnex commented, In addition to expanding our service offering in medical testing, this license provides Warnex with the exclusivity for JAK2 clinical testing performed in Canada, thus significantly enhancing our market position. Finding the JAK2 mutation is a major step forward in diagnosing myeloproliferative disorders.


Related Links:
Warnex
Ipsogen SAS

New
Gold Member
STI Test
Vivalytic MG, MH, UP/UU
Gold Member
Quantitative POC Immunoassay Analyzer
EASY READER+
New
HIV-1 Molecular Diagnostic Assay
AltoStar HIV RT-PCR Kit 1.5
New
Total Laboratory Automation Solution
SATLARS Mini T8
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: The device contains specific antibodies that capture the primary biomarker of pancreatic cancer. The binding of these antibodies alters the distribution of electrical charges on the electrode surface. The sensor then translates this variation into a measurable capacitance signal (photo courtesy of Gabriella Soares / IFSC-USP)

Rapid Biosensor Detects Pancreatic Cancer Biomarker for Early Detection

Pancreatic cancer is frequently identified only after it has progressed because early disease is typically asymptomatic, and survival remains extremely poor once advanced. Conventional laboratory assays... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.